Modeling of the Instantaneous Transvalvular Pressure Gradient in Aortic Stenosis.

The simplified and modified Bernoulli equations break down in estimating the true pressure gradient across the stenotic aortic valve due to their over simplifying assumptions of steady and inviscid conditions as well as the fundamental nature in which aortic valves are different than idealized orifices. Nevertheless, despite having newer models based on time-dependent momentum balance across an orifice, the simplified and modified Bernoulli continue to be the clinical standard because to date, they remain the only models clinically implementable. The objective of this study is to (1) illustrate the fundamental considerations necessary to accurately model the time-dependent instantaneous pressure gradient across a fixed orifice and (2) propose empirical corrections when applying orifice based models to severely stenotic aortic valves. We introduce a general model to predict the time-dependent instantaneous pressure gradient across an orifice that explicitly model the Reynolds number dependence of both the steady and unsteady terms. The accuracy of this general model is assessed with respect to previous models through pulse duplicator experiments on a round orifice model as well as an explanted stenotic surgical aortic valve both with geometric areas of 0.6 cm2 (less than 1 cm2 which is the threshold for stenosis determination) over cardiac outputs of 3 and 5 L/min and heart rates of 60, 90 and 120 bpm. The model and the raw experimental data corresponding to the orifice showed good agreement over a wide range of cardiac outputs and heart rates (R2 exceeding 0.91). The derived average and peak transvalvular pressure gradients also demonstrated good agreement with no significant differences between the respective peaks (p > 0.09). The new model proposed holds promise with its physical and closed form representation of pressure drop, however accurate modeling of the time-variability of the valve area is necessary for the model to be applied on stenotic valves.

GREB1 isoforms regulate proliferation independent of ERα co-regulator activities in breast cancer.

Activation of the transcription factor estrogen receptor α (ERα) and the subsequent regulation of estrogen-responsive genes play a crucial role in the development and progression of the majority of breast cancers. One gene target of ERα, growth regulation by estrogen in breast cancer 1 (GREB1), is associated with proliferation and regulation of ERα activity in estrogen-responsive breast cancer cells. The GREB1 gene encodes three distinct isoforms: GREB1a, GREB1b and GREB1c, whose molecular functions are largely unknown. Here, we investigate the role of these isoforms in regulation of ERα activity and proliferation. Interaction between GREB1 and ERα was mapped to the amino terminus shared by all GREB1 variants. Analysis of isoform-specific regulation of ERα activity suggests none of the GREB1 isoforms possess potent co-regulator activity. Exogenous expression of GREB1a resulted in elevated expression of some ER-target genes, independent of ERα activity. Despite this slight specificity of GREB1a for gene regulation, exogenous expression of either GREB1a or GREB1b resulted in decreased proliferation in both ER-positive and ER-negative breast carcinoma cell lines, demonstrating an ER-independent function of GREB1. Interestingly, we show an increase in the expression of GREB1b and GREB1c mRNA in malignant breast tissue compared to normal patient samples, suggesting a selective preference for these isoforms during malignant transformation. Together, these data suggest GREB1a has an isoform-specific function as a transcriptional regulator while all isoforms share an ER-independent activity that regulates proliferation.

Varying Susceptibility of the Female Mammary Gland to In Utero Windows of BPA Exposure.

In utero exposure to the endocrine disrupting compound bisphenol A (BPA) is known to disrupt mammary gland development and increase tumor susceptibility in rodents. It is unclear whether different periods of in utero development might be more susceptible to BPA exposure. We exposed pregnant CD-1 mice to BPA at different times during gestation that correspond to specific milestones of in utero mammary gland development. The mammary glands of early-life and adult female mice, exposed in utero to BPA, were morphologically and molecularly (estrogen receptor-α and Ki67) evaluated for developmental abnormalities. We found that BPA treatment occurring before mammary bud invasion into the mesenchyme [embryonic day (E)12.5] incompletely resulted in the measured phenotypes of mammary gland defects. Exposing mice up to the point at which the epithelium extends into the precursor fat pad (E16.5) resulted in a nearly complete BPA phenotype and exposure during epithelial extension (E15.5 to E18.5) resulted in a partial phenotype. Furthermore, the relative differences in phenotypes between exposure windows highlight the substantial correlations between early-life molecular changes (estrogen receptor-α and Ki67) in the stroma and the epithelial elongation defects in mammary development. These data further implicate BPA action in the stroma as a critical mediator of epithelial phenotypes.

SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy.

BACKGROUND: Spinal Muscular Atrophy (SMA) is an autosomal recessive motor neuron disease that results in loss of spinal motor neurons, muscular weakness and, in severe cases, respiratory failure and death. SMA is caused by a deletion or mutation of the SMN1 gene and retention of the SMN2 gene that leads to low SMN expression levels.The measurement of SMN mRNA levels in peripheral blood samples has been used in SMA clinical studies as a pharmacodynamic biomarker for response to therapies designed to increase SMN levels. We recently developed a postnatal porcine model of SMA by the viral delivery of a short-hairpin RNA (shRNA) targeting porcine SMN (pSMN). scAAV9-mediated knockdown of pSMN mRNA at postnatal day 5 results in denervation, weakness and motor neuron and ventral root axon loss that begins 3-4 weeks after viral delivery, and this phenotype can be ameliorated by subsequent viral delivery of human SMN (hSMN). OBJECTIVE: To determine if the effect of modulating SMN levels using gene therapy can be measured in blood. METHODS: We measured expression of pSMN mRNA and hSMN mRNA by quantitative droplet digital PCR (ddPCR). RESULTS: We found that the endogenous expression of pSMN mRNA in blood increases in the first month of life. However, there were no significant differences in blood levels of pSMN mRNA after knock-down or of human SMN mRNA after gene therapy. CONCLUSIONS: Our results, obtained in a large animal model of SMA that is similar in size and anatomy to human infants, suggest that measurement of SMN mRNA levels in blood may not be informative in SMA clinical trials involving intrathecal delivery of SMN-modulating therapies.